| Literature DB >> 27403940 |
Miguel A Garcia-Knight1,2, Jennifer Slyker3, Barbara Lohman Payne4,5, Sergei L Kosakovsky Pond6, Thushan I de Silva7, Bhavna Chohan3,8, Brian Khasimwa8, Dorothy Mbori-Ngacha4, Grace John-Stewart3,5,9,10, Sarah L Rowland-Jones1, Joakim Esbjörnsson1,11.
Abstract
Antiretroviral therapy-naive HIV-1 infected infants experience poor viral containment and rapid disease progression compared to adults. Viral factors (e.g. transmitted cytotoxic T- lymphocyte (CTL) escape mutations) or infant factors (e.g. reduced CTL functional capacity) may explain this observation. We assessed CTL functionality by analysing selection in CTL-targeted HIV-1 epitopes following perinatal infection. HIV-1 gag, pol and nef sequences were generated from a historical repository of longitudinal specimens from 19 vertically infected infants. Evolutionary rate and selection were estimated for each gene and in CTL-restricted and non-restricted epitopes. Evolutionary rate was higher in nef and gag vs. pol, and lower in infants with non-severe immunosuppression vs. severe immunosuppression across gag and nef. Selection pressure was stronger in infants with non-severe immunosuppression vs. severe immunosuppression across gag. The analysis also showed that infants with non-severe immunosuppression had stronger selection in CTL-restricted vs. non-restricted epitopes in gag and nef. Evidence of stronger CTL selection was absent in infants with severe immunosuppression. These data indicate that infant CTLs can exert selection pressure on gag and nef epitopes in early infection and that stronger selection across CTL epitopes is associated with favourable clinical outcomes. These results have implications for the development of paediatric HIV-1 vaccines.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27403940 PMCID: PMC4941567 DOI: 10.1038/srep29536
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Infant characteristics.
| Infant ID | Sex | MOT | Peak VL | CD4% nadir | Age last seen, mo | #Of sequences/TP | HLA A; B; C | Subtype | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 135 | M | IU | 7.65 | 2 (4) | 15 | 4 | 0 | 4 | 32, 6802; 39, 44; 04, 12 | A1 |
| 159 | F | P | 6.94 | 18 (4) | 24 | 6 | 1 | 4 | 29, 30; 4501, 4501; 06, 06 | A1 |
| 168 | M | P | 8.15 | 6 (4) | 18 | 6 | 3 | 6 | 24, 29 ;15, 5802; 02, 04 | URF |
| 170 | M | IU | 5.94 | 17 (3) | 18 | 4 | 4 | 4 | 30, 3402; 4201/2, 57; 07, 17 | A1 |
| 211 | M | P | 7.63 | 17 (4) | 24 | 6 | 4 | 6 | 30, 6802; 4201/2, 4201/2; 07, 17 | URF |
| 231 | F | P | 6.26 | 18 (4) | 24 | 4 | 4 | 4 | 26, 34; 35, 53; 04, 04 | URF |
| 258 | M | IU | 6.68 | 20 (3) | 12 | 4 | 4 | 2 | 03, 30; 15, 7301;15, 17 | A1 |
| 259 | M | P | 7.24 | 34 (4) | 24 | 3 | 4 | 3 | 23, 74; 58, 4501; 07, 07 | A1 |
| 261 | F | P | 6.57 | 16 (4) | 24 | 5 | 3 | 5 | 2, 29; 5802, 35; 06, 07 | URF |
| 281 | M | P | 6.60 | 21 (3) | 12 | 4 | 3 | 4 | 23, 74; 15, 15; 02, 02 | A1 |
| 291 | M | P | 7.23 | 9 (6) | 15 | 6 | 4 | 6 | 29, 74; 4201/2, 15; 02, 17 | A1 |
| 303 | M | P | 7.62 | 17 (4) | 12 | 2 | 3 | 1 | 30, 30; 4501, 4501; 1601, 1601 | D |
| 313 | M | IU | 7.45 | 12 (6) | 24 | 4 | 2 | 3 | 33, 6802; 15, 35; 03, 04 | URF |
| 334 | F | P | 6.46 | 24 (4) | 9 | 4 | 0 | 4 | 29, 26/66; 13, 15; 02, 06 | A1 |
| 411 | F | P | 7.15 | 15 (5) | 24 | 4 | 4 | 4 | 30, 30; 15, 42; 14, 17 | A1 |
| 424 | F | IU | 7.45 | 7 (2) | 6 | 3 | 2 | 3 | 02, 6802; 51, 08; 07, 1601 | URF |
| 440 | M | IU | 6.88 | 10 (3) | 10 | 4 | 1 | 3 | 02, 30; 4501/03, 4902; 06, 1601 | A1 |
| 454 | M | P | 7.64 | 23 (5) | 24 | 4 | 4 | 4 | 02, 31; 08, 15; 07, 08 | URF |
| 485 | M | IU | 6.39 | 4 (7) | 24 | 4 | 3 | 2 | NA; NA; NA | A1 |
*Maximum VL measurement within 6 months of infection, log10 HIV-1 plasma RNA copies/mL of plasma.
†Within 15 months of age. TP, time points; NA, not available; VL, viral load; mo, months; MOT, mode of transmission; IU, in utero; P, peripartum; URF, unique recombinant form, parental subtypes shown in S3 Table.
Figure 1Evolutionary rates across HIV-1 gag, pol and nef genes from infants sampled under 2 years of age.
(A) Summary of nucleotide substitution rates across gag, pol and nef with median (line) 1st and 3rd quartiles (box) and the 10th and 90th percentile (whiskers) shown. The Mann Whitney U test was used to assess differences between groups. (B) Rank-based Spearman correlations between the nucleotide substitution rate across gag and nef.
Global evolutionary rates and dN/dS rate ratios in infants stratified by clinical parameters.
| Gene | Immunosuppression | Peak VL | Mode of transmission | HIV subtype | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NSIS | SIS | < Median | > Median | A1 | Other | |||||||
| N = 10 | N = 8 | N = 9 | N = 9 | N = 7 | N = 11 | N = 11 | N = 7 | |||||
| 4.2 (3.0–5.0) | 8.8 (7.0–11.0) | 6.1 (5.0–7.0) | 5.8 (5.0–7.0) | 0.8 (0.07) | 6.7 (5.0–9.0) | 5.7 (5.0–7.0) | 0.4 (0.8) | 6.0 (5.0–7.0) | 5.9 (5.0–8.0) | 1.0 (0.0) | ||
| 1.4 (1.1–1.8) | 0.4 (0.3–0.5) | 0.9 (0.7–1.2) | 0.5 (0.4–0.7) | 0.08 (3.0) | 0.4 (0.3–0.6) | 0.8 (0.6–1.0) | 0.1 (2.4) | 0.7 (0.5–0.8) | 0.6 (0.5–0.9) | 0.8 (0.05) | ||
| N = 9 | N = 4 | N = 9 | N = 4 | N = 3 | N = 10 | N = 7 | N = 6 | |||||
| 1.4 (1.0–2.0) | 2.1 (1.0–3.0) | 0.2 (1.8) | 1.4 (1.0–2.0) | 1.6 (1.0–2.0) | 0.7 (0.2) | 1.0 (0.0–2.0) | 1.6 (1.0–2.0) | 0.3 (0.9) | 1.5 (1.0–2.0) | 1.6 (1.0–2.0) | 0.9 (0.02) | |
| 0.3 (0.2–0.5) | 0.3 (0.1–0.5) | 1.0 (0.00) | 0.2 (0.1–0.4) | 0.4 (0.2–0.6) | 0.3 (1.2) | 1.1 (0.2–2.8) | 0.2 (0.1–0.4) | 0.2 (1.9) | 0.4 (0.2–0.7) | 0.2 (0.09–0.4) | 0.2 (1.4) | |
| N = 9 | N = 7 | N = 7 | N = 9 | N = 5 | N = 11 | N = 9 | N = 7 | |||||
| 8.0 (6.0–11) | 19.4 (15.0–25.0) | 6.7 (4.0–10.0) | 16.6 (13.0–20.0) | 14.1 (9.0–20.0) | 12.1 (10.0–15.0) | 0.5 (0.5) | 9.0 (6.0–12.0) | 16.1 (13.0–20.0) | ||||
| 1.1 (0.8–1.5) | 0.6 (0.4–0.8) | 0.2 (1.8) | 0.7 (0.4– 1.2) | 0.8 (0.6–1.0) | 1.0 (0.00) | 0.4 (2.0–0.6) | 1.0 (0.8–1.3) | 0.03(4.9) | 0.8 (0.5–1.1) | 0.8 (0.6–1.0) | 1.0 (0.0) | |
*Median of N = 19 infants. †Rate = nucleotide substitutions/1000 sites/year. NSIS, non-severely immunosuppressed (CD4% >15 during follow-up). SIS, severely immunosuppressed (CD4% ≤15 during follow-up). VL, viral load; LRT, likelihood ratio test. Bold indicates significant values after correction for multiple comparisons.
dN/dS rate ratios across gag and nef in HLA and non-HLA targeted epitopes in infants stratified by immunosuppression.
| Gene | Parameter | d | |||
|---|---|---|---|---|---|
| CTL+ | CTL- | LRT | |||
| NSIS (N = 10) | 2.3 (1.6–3.3) | 1.0 (0.7–1.5) | 7.6 | ||
| SIS ( | 0.5 (0.3–0.8) | 0.4 (0.3–0.5) | 0.717 | 0.1 | |
| NSIS (N = 9) | 2.6 (1.7–3.8) | 0.5 (0.2–0.8) | 20.4 | ||
| SIS (N = 7) | 0.7 (0.4–1.1) | 0.6 (0.4–0.8) | 0.525 | 0.4 | |
SIS, severely immunosuppressed; NSIS, non-severely immunosuppressed; LRT, likelihood ratio test. *HLA data missing from infant 485.